Archived Press Releases – 2018

April 30, 2018

4DMT and ROCHE Expand Ophthalmology Partnership to Develop and Commercialize Multiple AAV Gene Therapy Products

Emeryville, CA, April 30, 2018 — 4D Molecular Therapeutics (4DMT), a leader in Therapeutic Vector Evolution for adeno-associated virus (AAV) gene therapy vector discovery and product development, today announced the expansion of its 2015 research agreement with F. Hoffmann-La Roche ...

September 5, 2018

4D Molecular Therapeutics Raises $90 Million Series B Financing

- Proceeds advance proprietary next-generation Therapeutic Vector Evolution platform and pipeline of AAV gene therapy clinical candidates - - Lead product candidate 4D-110 in Choroideremia to enter clinic in 2019 - - Financing led by Viking Global Investors - Emeryville, ...